Daily News Podcast

Brain damage, slight benefit seen in epinephrine cardiac arrest


 

Epinephrine provided a slight 30-day survival benefit, but those patients experienced more severe brain damage. Also today, nerve growth factor inhibitor shows phase-3 efficacy in osteoarthritis, National Academies issues a 5-step plan to address infections linked to opioid use disorder, and there may be beneficial class effects of SGLT2 inhibitors, including dapagliflozin. Listen to the MDedge Daily News for today’s top news.

Recommended Reading

Judge Brett Kavanaugh and the ACA
MDedge Endocrinology
New guidelines could mean millions more with hypertension
MDedge Endocrinology
AHRQ National Guideline Clearinghouse shutting down
MDedge Endocrinology
Less documentation highlights new Medicare fee proposal
MDedge Endocrinology
Too many antibiotics prescribed in urgent care
MDedge Endocrinology
CREDENCE canagliflozin trial halted because of efficacy
MDedge Endocrinology
Managing HIV with diabetes
MDedge Endocrinology
Telemedicine payment expansion?
MDedge Endocrinology
Most transgender teens not willing to delay hormone therapy to preserve fertility
MDedge Endocrinology
Bundle pay plan didn’t save money
MDedge Endocrinology